This drug may cause side effects, including but not limited to dizziness, drowsiness, insomnia, dry mouth, sweating, decreased appetite
A mean increase in HR of 1.86 beats/min was reported in a meta-analysis including available data from randomized controlled trials testing GLP-1 agonists against placebo in patients with T2D [53]
Tirzepatide is the first and only dual agonist of GIP and GLP-1, which makes it a very unique proposition
Different medical options produce different results, with weight loss probabilities ranging from 23.1% for nutrition counseling to 93.0% for bariatric surgery, and structured plans that may include meal replacement can lead to 15-30 kg of loss in 12-20 weeks
Because muscles burn more calories and require more energy than fat, changes in muscle mass are common
Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes
